Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

You may be eligible for inclusion in the above clinical trial, which has study centres in Arizona, Florida, and New York in the USA and in Heidelberg, Cologne, Bologna, Naples, and St Gallen in Europe. The aim of the study is to examine the effects of the novel treatment tinostamustine in those patients with certain blood cancers who have failed previous therapies.

If you wish to be considered for this study, you should contact your healthcare professional and they will assess your suitability and if appropriate, refer you to the centre undertaking the trial.

To take part in this trial, you will have to meet certain requirements, which include: Age ≥18 years, that you are not currently pregnant and/or breastfeeding and that you have not recently participated in a clinical trial.